Security
Pulmatrix, Inc. Common Stock · PULM
PULMNASDAQCommon stockCurrentCIK 1574235Updated Nov 10, 2026
Name history
Ruthigen, Inc. · through Jun 16, 2015
PULM price & chart
Loading TradingView…
NASDAQ:PULM on TradingView ↗About the company
company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology. Pulmatrix’s proprietary product pipeline includes treatments for central nervous system (“CNS”) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (“COPD”) and allergic bronchopulmonary aspergillosis (“ABPA”). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE™, which seeks to improve therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. For more on Pulmatrix’s inhaled product candidates, please visit: https://www.pulmatrix.com/pipeline.html.
In the news
Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets News provided by Pulmatrix Inc. Oct 16, 2025, 08:05 ET Share this article Share to X Share this article Share to X As part of the proposed merger, Pulmatrix currently intends to divest its ↗
Recent filings
425 filing
425 filing
Submission of Matters to a Vote of Security Holders
Items 5.07
424B3 filing
EFFECT filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 4,982,000Source | 11,510,000Source | 3,246,000Source | 6,152,000Source | 15,780,000Source | 4,496,000Source | 8,051,000Source | 30,391,000Source | 4,139,000Source | 9,943,000Source | 33,958,000Source | 40,953,000Source |
| Property, Plant and Equipment, NetUSD | — | — | — | — | — | — | — | 1,108,000Source | — | — | 1,158,000Source | 235,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 4,794,000Source | 10,782,000Source | 2,168,000Source | 5,825,000Source | 12,379,000Source | 3,324,000Source | 7,708,000Source | 16,300,000Source | 4,088,000Source | 9,521,000Source | 19,173,000Source | 35,628,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | 23,000Source | — | — | 635,000Source | — | 16,000Source | 570,000Source | — | — | 928,000Source | 1,298,000Source |
| Assets, CurrentUSD | 4,972,000Source | 11,446,000Source | 3,239,000Source | 6,142,000Source | 15,636,000Source | 4,489,000Source | 8,041,000Source | 17,582,000Source | 4,129,000Source | 9,920,000Source | 20,843,000Source | 38,147,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 178,000Source | 641,000Source | 371,000Source | 317,000Source | 1,201,000Source | 465,000Source | 317,000Source | 712,000Source | 41,000Source | 399,000Source | 742,000Source | 1,068,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | — | — | — | — | — | 10,094,000Source | — | — | 10,309,000Source | 710,000Source |
| Other Assets, NoncurrentUSD | — | 54,000Source | — | — | 93,000Source | — | — | 135,000Source | — | 13,000Source | 176,000Source | 389,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 249,000Source | 590,000Source | 689,000Source | 548,000Source | 2,470,000Source | 905,000Source | 904,000Source | 11,373,000Source | 329,000Source | 996,000Source | 15,963,000Source | 9,844,000Source |
| Stockholders’ equity: | ||||||||||||
| Additional Paid in CapitalUSD | 306,123,000Source | 306,090,000Source | 306,117,000Source | 306,117,000Source | 305,893,000Source | 306,131,000Source | 306,111,000Source | 305,790,000Source | 306,128,000Source | 306,103,000Source | 305,592,000Source | 304,585,000Source |
| Retained Earnings (Accumulated Deficit)USD | -301,390,000Source | -295,170,000Source | -304,526,000Source | -300,513,000Source | -292,583,000Source | -303,490,000Source | -298,964,000Source | -286,772,000Source | -302,318,000Source | -297,156,000Source | -287,597,000Source | -273,476,000Source |
| Stockholders' Equity Attributable to ParentUSD | 4,733,000Source | 10,920,000Source | 2,557,000Source | 5,604,000Source | 13,310,000Source | 3,591,000Source | 7,147,000Source | 19,018,000Source | 3,810,000Source | 8,947,000Source | 17,995,000Source | 31,109,000Source |
| Liabilities and EquityUSD | 4,982,000Source | 11,510,000Source | 3,246,000Source | 6,152,000Source | 15,780,000Source | 4,496,000Source | 8,051,000Source | 30,391,000Source | 4,139,000Source | 9,943,000Source | 33,958,000Source | 40,953,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 249,000Source | 590,000Source | 689,000Source | 548,000Source | 2,470,000Source | 905,000Source | 903,000Source | 3,144,000Source | 329,000Source | 929,000Source | 3,909,000Source | 5,022,000Source |
| Operating Lease, Liability, CurrentUSD | — | — | — | — | 24,000Source | — | — | 383,000Source | — | — | 429,000Source | 857,000Source |
| Accounts Payable, CurrentUSD | 69,000Source | 373,000Source | 529,000Source | 384,000Source | 393,000Source | 651,000Source | 657,000Source | 721,000Source | 272,000Source | 809,000Source | 1,915,000Source | 1,188,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | — | — | — | — | — | 8,229,000Source | — | — | 8,327,000Source | — |
| Additional Financial Items | ||||||||||||
| Deferred Revenue, CurrentUSD | — | — | — | — | 270,000Source | — | — | 363,000Source | — | — | 618,000Source | 1,339,000Source |
| Deferred Revenue, NoncurrentUSD | — | — | — | — | — | — | — | — | — | — | 3,727,000Source | 4,822,000Source |
| Preferred Stock, Value, Issued | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | — | — | — | 106,000Source | 134,000Source | 162,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | 2,000Source | 6,000Source | 3,000Source | 8,000Source | 25,000Source | 511,000Source | 954,000Source | 1,114,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | 16,000Source | — | -928,000Source | -370,000Source | 1,231,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 379,000Source | -152,000Source | -537,000Source | -1,106,000Source | 727,000Source | 511,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -1,067,000Source | -1,813,000Source | -5,433,000Source | -10,716,000Source | -15,985,000Source | -19,356,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | — | -398,000Source | -676,000Source | -86,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | 398,000Source | 676,000Source | 86,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 1,000,000Source | — | — | — | 53,000Source | 1,230,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -67,000Source | -1,813,000Source | -5,433,000Source | -11,114,000Source | -16,608,000Source | -18,212,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 6,000Source | 197,000Source | — | 6,000Source | — | 8,000Source | 25,000Source | 511,000Source | 954,000Source | 1,114,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | -2,618,000Source | -8,000Source | — |
| Gain (Loss) on Termination of LeaseUSD | — | — | — | — | — | — | — | — | — | -2,618,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 858,000Source | 2,209,000Source | 1,044,000Source | 1,534,000Source | 1,289,000Source | 1,828,000Source | 5,131,000Source | 7,785,000Source | 6,520,000Source | 6,778,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | — | 0Source | — | 0Source | 0Source | — | — | — |
| Investment Income, InterestUSD | — | — | 30,000Source | 101,000Source | 10,000Source | 41,000Source | 12,000Source | 53,000Source | 144,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -877,000Source | -2,587,000Source | -1,036,000Source | -1,549,000Source | -1,172,000Source | -1,808,000Source | -5,162,000Source | -9,559,000Source | -14,121,000Source | -18,836,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | -1,052,000Source | -1,549,000Source | — | — | — | — | — | -18,836,000Source |
| Nonoperating Income (Expense)USD | — | — | -11,000Source | 70,000Source | 10,000Source | -1,000Source | 120,000Source | 39,000Source | 7,000Source | 204,000Source | 619,000Source | 111,000Source |
| Operating ExpensesUSD | — | — | 866,000Source | 3,023,000Source | 1,046,000Source | 1,548,000Source | 1,292,000Source | 1,847,000Source | 5,169,000Source | 17,569,000Source | 22,038,000Source | 25,018,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -41,000Source | -31,000Source | — | -43,000Source | 108,000Source | -80,000Source | -204,000Source | -196,000Source | -248,000Source | -198,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | 53,000Source | 1,382,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | 366,000Source | — | — | — | — | — | 7,806,000Source | 7,298,000Source | 6,071,000Source |
| Operating Income (Loss)USD | — | — | -866,000Source | -2,657,000Source | -1,046,000Source | -1,548,000Source | -1,292,000Source | -1,847,000Source | -5,169,000Source | -9,763,000Source | -14,740,000Source | -18,947,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -41,000Source | -31,000Source | — | -43,000Source | 108,000Source | -80,000Source | -204,000Source | -196,000Source | -248,000Source | -198,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | — | 0Source | — | 0Source | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -877,000Source | -2,587,000Source | -1,036,000Source | -1,549,000Source | -1,172,000Source | -1,808,000Source | -5,162,000Source | -9,559,000Source | -14,121,000Source | -18,836,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.24Source | -0.71Source | -0.29Source | -0.42Source | -0.32Source | -0.5Source | -1.41Source | -2.62Source | -3.87Source | -5.46Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.24Source | -0.71Source | -0.29Source | -0.42Source | -0.32Source | -0.5Source | -1.41Source | -2.62Source | -3.87Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 3,652,285Source | 3,652,285Source | 3,652,285Source | 3,652,285Source | 3,652,285Source | 3,652,285Source | 3,652,285Source | 3,652,285Source | 3,651,911,000Source | 3,447,701Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 3,652,285Source | 3,652,285Source | 3,652,285Source | 3,652,285Source | 3,652,285Source | 3,652,285Source | 3,652,285Source | 3,652,285Source | 3,651,911,000Source | — |
| Additional Financial Items | ||||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | — | — | — | 106,000Source | 134,000Source | 162,000Source |
| General and Administrative ExpenseUSD | — | — | 858,000Source | 2,209,000Source | 1,044,000Source | 1,534,000Source | 1,289,000Source | 1,828,000Source | 5,131,000Source | 7,785,000Source | 6,520,000Source | 6,778,000Source |
| Interest Income (Expense), NetUSD | — | — | — | 101,000Source | — | — | — | 53,000Source | — | 467,000Source | 867,000Source | 309,000Source |
| Investment Income, InterestUSD | — | — | 30,000Source | 101,000Source | 10,000Source | 41,000Source | 12,000Source | 53,000Source | 144,000Source | — | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | -1,052,000Source | -1,549,000Source | — | — | — | — | — | -18,836,000Source |
| Nonoperating Income (Expense)USD | — | — | -11,000Source | 70,000Source | 10,000Source | -1,000Source | 120,000Source | 39,000Source | 7,000Source | 204,000Source | 619,000Source | 111,000Source |
| Operating ExpensesUSD | — | — | 866,000Source | 3,023,000Source | 1,046,000Source | 1,548,000Source | 1,292,000Source | 1,847,000Source | 5,169,000Source | 17,569,000Source | 22,038,000Source | 25,018,000Source |
| Research and Development ExpenseUSD | — | — | 8,000Source | 814,000Source | 2,000Source | 14,000Source | 3,000Source | 19,000Source | 38,000Source | 7,166,000Source | 15,518,000Source | 18,240,000Source |
Offerings
Registration 333-296478
Registration 333-297342
Registration 333-284993
Filing attachments
ex107.htm · S-3/A · 2026-10-05
Calculation of Filing Fee Tables S-3 Pulmatrix, Inc. ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Pric…
Read attachment ↗ex4-7.htm · S-4/A · 2026-09-04
EX-4.7 2 ex4-7.htm EX-4.7 Exhibit 4.7 Form of Convertible Promissory Note THIS INSTRUMENT AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR UPON RECEIPT BY THE COMPANY OF AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION IS NOT …
Read attachment ↗ex99-1.htm · 8-K · 2026-08-13
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger Form S-4 filed related to the announced merger agreement with Eos SENOLYTIX Framingham, Mass., August 13, 2026 - Pulmatrix, Inc. (“Pulmatrix” or the “Company”) (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical…
Read attachment ↗ex107.htm · S-4 · 2026-07-09
Calculation of Filing Fee Tables S-4 Pulmatrix, Inc. ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Pric…
Read attachment ↗ex99-1.htm · S-4 · 2026-07-09
EX-99.1 13 ex99-1.htm EX-99.1 Exhibit 99.1 Consent to be Named as a Director Pulmatrix, Inc. is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a future member of the b…
Read attachment ↗ex99-2.htm · S-4 · 2026-07-09
EX-99.2 14 ex99-2.htm EX-99.2 Exhibit 99.2 Consent to be Named as a Director Pulmatrix, Inc. is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a future member of the b…
Read attachment ↗